XTL Biopharmaceuticals Ltd. to Present at the Rodman & Renshaw Techvest 7th Annual Healthcare Conference
03 November 2005 - 7:18PM
PR Newswire (US)
REHOVOT, Israel, November 3 /PRNewswire-FirstCall/ -- XTL
Biopharmaceuticals Ltd ("XTLbio") (NASDAQ:XTLB)(LSE:XTL)(TASE:XTL)
today announced that Ram Waisbourd, Vice President, Business
Development, will present an overview of the Company at the Rodman
& Renshaw Techvest 7th Annual Healthcare Conference in New York
City. Mr. Waisbourd's presentation will take place on Monday, 7
November 2005 at 8:10 pm UK time (3:10 pm EST) in the Adams Room at
the New York Palace Hotel. A live audio webcast of Mr. Waisbourd's
presentation will be available during the presentation at
http://www.wsw.com/webcast/rrshq7/xtlb/ and will be archived for a
period of 90 days, beginning approximately 3 hours following the
conclusion of the live presentation. Contacts: XTLbio Jonathan
Burgin, Chief Financial Officer Tel: +972-8-930-4440 About XTL
Biopharmaceuticals Ltd. Established in 1993, XTL Biopharmaceuticals
Ltd. (LSE:XTL)(NASDAQ:XTLB) ( TASE: XTL) is a biopharmaceutical
company engaged in the acquisition, development and
commercialization of pharmaceutical products for the treatment of
infectious diseases, particularly the prevention and treatment of
hepatitis B and C. Cautionary Statement Some of the statements
included in this press release may be forward-looking statements
that involve a number of risks and uncertainties. For those
statements, we claim the protection of the safe harbor for
forward-looking statements contained in the US Private Securities
Litigation Reform Act of 1995. Among the factors that could cause
our actual results to differ materially, and therefore affect
interest by investors in our securities, are the following: the
results of prior trails with XTL-686are not necessarily indicative
of the results we may have in the Phase 1a and 1b trials; and other
risk factors identified from time to time in our reports filed with
the various regulatory bodies. Any forward-looking statements set
forth in this press release speak only as of the date of this press
release. We do not intend to update any of these forward-looking
statements to reflect events or circumstances that occur after the
date hereof. This press release and prior releases are available at
http://www.xtlbio.com/. The information in our website is not
incorporated by reference into this press release and is included
as an inactive textual reference only. DATASOURCE: XTL
Biopharmaceuticals Ltd. CONTACT: Contacts: XTLbio: Jonathan Burgin,
Chief Financial Officer, Tel: +972-8-930-4440
Copyright
XTL Biopharmaceuticals (NASDAQ:XTLB)
Historical Stock Chart
From Jun 2024 to Jul 2024
XTL Biopharmaceuticals (NASDAQ:XTLB)
Historical Stock Chart
From Jul 2023 to Jul 2024